Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 349

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

Open access
Lin, Jessica J., Zhu, Viola W., Yoda, Satoshi, Yeap, Beow Y., Schrock, Alexa B., Dagogo-Jack, Ibiayi, Jessop, Nicholas A., Jiang, Ginger Y., Le, Long P., Gowen, Kyle, Stephens, Philip J., Ross, Jeffrey S., Ali, Siraj M., Miller, Vincent A., Johnson, Melissa L., Lovly, Christine M., Hata, Aaron N., Gainor, Justin F., Iafrate, Anthony J., Shaw, Alice T., Ou, Sai-Hong Ignatius·2018·Journal of Clinical Oncology

Abstract

Purpose: Advanced anaplastic lymphoma kinase ( ALK) fusion-positive non–small-cell lung cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs). However, clinical outcomes in these patients vary, and the benefit of TKIs is limited as a result of acquired resistance. Emerging data suggest that the ALK fusion variant may affect clinical outcome, but the molecular basis for this association is unknown. Patients and Methods: We identified 129 patients with ALK-positive NSCLC with known ALK variants. ALK resistance mutations and clinical outcomes on ALK TKIs were retrospectively evaluated according to ALK variant. A Foundation Medicine data set of 577 patients with ALK-positive NSCLC was also examined. Results: The most frequent ALK variants were EML4-ALK variant 1 in 55 patients (43%) and variant 3 in 51 patients (40%). We analyzed 77 tumor biopsy specimens from patients with variants 1 and 3 who had progressed on an ALK TKI. ALK resistance mutations were significantly more common in variant 3 than in variant 1 (57% v 30%; P = .023). In particular, ALK G1202R was more common in variant 3 than in variant 1 (32% v 0%; P < .001). Analysis of the Foundation Medicine database revealed similar associations of variant 3 with ALK resistance mutation and with G1202R ( P = .010 and .015, respectively). Among patients treated with the third-generation ALK TKI lorlatinib, variant 3 was associated with a significantly longer progression-free survival than variant 1 (hazard ratio, 0.31; 95% CI, 0.12 to 0.79; P = .011). Conclusion: Specific ALK variants may be associated with the development of ALK resistance mutations, particularly G1202R, and provide a molecular link between variant and clinical outcome. ALK variant thus represents a potentially important factor in the selection of next-generation ALK inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.76.2294

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 349

Metadata

Authors
Lin, J. J., Zhu, V. W., Yoda, S., Yeap, B. Y., Schrock, A. B., Dagogo-Jack, I., Jessop, N. A., Jiang, G. Y., Le, L. P., Gowen, K., Stephens, P. J., Ross, J. S., Ali, S. M., Miller, V. A., Johnson, M. L., Lovly, C. M., Hata, A. N., Gainor, J. F., Iafrate, A. J., Shaw, A. T., & Ou, S.-H. I.
Venue
Journal of Clinical Oncology
Published
2018-04-20
Volume
36
Issue
12
Pages
1199-1206
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2785110924
Cited by
349
References
44
FWCI
32.30
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.2017.76.2294
The paper
Lin, J. J., Zhu, V. W., Yoda, S., Yeap, B. Y., Schrock, A. B., Dagogo-Jack, I., Jessop, N. A., Jiang, G. Y., Le, L. P., Gowen, K., Stephens, P. J., Ross, J. S., Ali, S. M., Miller, V. A., Johnson, M. L., Lovly, C. M., Hata, A. N., Gainor, J. F., Iafrate, A. J., . . . Ou, S.-H. I. (2018). Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.76.2294

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.